Updated:
MedCrypt
Fast-track FDA readiness with proven medical device cybersecurity expertise. Zero FDA rejections to date. Guardian & Helm platforms accelerate regulatory...
MedCrypt
Fast-track FDA readiness with proven medical device cybersecurity expertise. Zero FDA rejections to date. Guardian & Helm platforms accelerate regulatory approval.
General information
Firm type
other
Year founded
2016
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Solana Beach
Corporate office
Solana Beach, CA, United States
Principals
Mike Kijewski
CEO
Eric Pancoast
CTO
Vidya Murthy
Manager (security)
Axel Wirth
Chief Security Strategist
Seth Carmody
Director of Cybersecurity Strategy
Naomi Schwartz
Regulatory and Compliance Expert
Om Mahida
VP of Product
AJ Reiter
VP of Operations and Strategy
William Fenstermaker
VP of DevOps
Sector focus
Frequently asked questions
Who runs product and engineering at MedCrypt?
Om Mahida is VP of Product, Eric Pancoast is CTO, and William Fenstermaker is VP of DevOps. Mike Kijewski serves as CEO (per firm website).
How does MedCrypt source its regulatory intelligence?
MedCrypt built what it calls Enforcement Intelligence — proprietary data on what FDA reviewers are actually enforcing, catching, and rejecting. The company claims no competitor can replicate this dataset (per firm website).
Does MedCrypt only sell to large medical device manufacturers?
MedCrypt states it works with companies of all sizes, from startups to enterprise-level medical device manufacturers (per firm website). Its client testimonials include both small startups and top device makers.
What investment stages did MedCrypt's Series A and B cover?
The Series A in 2019 was led by Section 32 with participation from Eniac Ventures and Y Combinator. The Series B in 2022 included Intuitive Ventures, Johnson & Johnson Innovation, and Dexcom Ventures, bringing total disclosed funding to $36.4M (per firm website).
Is MedCrypt a single-family office or a venture-backed company?
MedCrypt is a venture-backed cybersecurity company, not a family office. It has raised $36.4M in disclosed funding from institutional venture investors and corporate venture arms (per firm website).
What distinguishes MedCrypt's Helm product from other SBOM tools?
MedCrypt claims Helm eliminates the false positive problem common in vulnerability management tools. It published a side-by-side comparison against Grype, Dependency Track, and Blackduck (per firm website).
Does MedCrypt have any university research partnerships?
Yes. MedCrypt has financed research partnerships with Kansas State University to develop a cybersecurity risk prioritization platform and with Tufts University for a fellowship on medical device threat modeling (per firm website).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: